Update on the Long-Term Applications of Amikacin-Based Inhalation Therapeutics for the Treatment of Non-Tuberculous Mycobacterial Lung Disease


Program Dates: October 29th, 2021 - October 28th, 2022
Credits: 1.0 AMA PRA Category 1 Credit™


Update on the Long-Term Applications of Amikacin-Based Inhalation Therapeutics for the Treatment of Non-Tuberculous Mycobacterial Lung Disease

Program Overview

This CME program is derived from content presented at the Eastern Pulmonary Conference Annual Meeting. The expert faculty, Dr. Anne E. O’Donnell, will first highlight the pathophysiology, prevalence, and high-risk subgroups of non-tuberculous mycobacterial lung disease (NTM-LD). Following, Dr. O’Donnell will analyze current strategies for determining immunocompetent hosts and detecting radiographic manifestations in NTM-LD. The clinical implications of recent trial data for inhaled amikacin liposome therapeutics, including longer-term data and future considerations, will be reviewed. Upon completion of this activity, learners will be better equipped with current resources to provide optimal, tailored treatment for patients with NTM-LD.

Target Audience

Pulmonologists and other healthcare providers who are involved in the care and treatment of patients with nontuberculous mycobacterial lung disease (MAC lung disease)

Learning Objectives

  1. Review the science, diagnostic recommendations, and disease burden of nontuberculous mycobacterial lung disease (NTM-LD) caused by mycobacterium avium complex (MAC)
  2. Analyze clinical applications and longer-term data for amikacin liposome inhalation therapeutics for the treatment of MAC lung disease

Agenda

I. MAC Lung Disease Diagnostic Recommendations, Disease Burden, and Scientific Update

II. Data Review and Clinical Applications for Inhaled Amikacin Liposome Therapeutics for the Treatment of Patients with MAC Lung Disease

Faculty 

Anne E. O’Donnell MD
Professor of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
The Nehemiah and Naomi Cohen Chair in Pulmonary Disease Research
Georgetown University Medical Center
Washington, DC

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Anne E. O’Donnell MD

 

Consultant/Advisor: AbbVie, Inc.; Actelion; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; CSL Behring; Horizon Therapeutics USA, Inc.; Janssen Global Services, LLC; Prometheus Biosciences; Mitsubishi Tanabe Pharma Corporation

Grant/Research Support: Bristol Myers Squibb Company; Horizon Therapeutics USA, Inc.; Pfizer Inc.

Stockholder: Eicos Sciences, Inc.

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Insmed

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Insmed do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web